ADIM
BXC icon

Alpha DNA Investment Management’s BlueLinx BXC Stock Holding History

Alpha DNA Investment Management’s Portfolio BXC Stock Details BXC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-13,817
Closed -$922K – 158
2022
Q2 		$922K Buy
+13,817
New +$1.04M 0.79% 88

Other funds holding BXC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NC
Nokomis Capital Dallas, Texas $349M AUM 75.66% 1-Year Est. Return
JCP
JB Capital Partners Armonk, New York $581M AUM 46.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Alpha DNA Investment Management's BXC Position: Q3 2022 in Review

Alpha DNA Investment Management sold out of BlueLinx (BXC) in Q3 2022, closing a stake of 13,817 shares — an estimated $922K sold.

Alpha DNA Investment Management first reported a position in BXC in Q2 2022 and held it in 1 quarter. The position peaked at $922K in Q2 2022. 154 funds tracked by Wall St. Rank hold BXC as of Q3 2022.

  • Alpha DNA Investment Management reported no remaining BlueLinx position as of Q3 2022 after selling out during the quarter.
  • Alpha DNA Investment Management sold 13,817 BlueLinx shares in Q3 2022, an estimated $922K.
  • Alpha DNA Investment Management first reported a position in BlueLinx in Q2 2022 and held it in 1 quarter.
  • Alpha DNA Investment Management's BlueLinx position peaked at $922K in Q2 2022.
  • 154 funds tracked by Wall St. Rank held BlueLinx as of Q3 2022.

Based on Alpha DNA Investment Management's 13F filing for Q3 2022, filed 15 Nov 2022.